R1	Has_value Arg1:T2 Arg2:T1	
*	OR T3 T4
R2	Has_value Arg1:T6 Arg2:T7	
R3	AND Arg1:T5 Arg2:T6	
R4	Has_temporal Arg1:T10 Arg2:T11	
R5	AND Arg1:T10 Arg2:T8	
R6	Has_value Arg1:T8 Arg2:T9	
R7	Has_value Arg1:T15 Arg2:T16	
R8	Has_value Arg1:T13 Arg2:T14	
R9	Subsumes Arg1:T12 Arg2:T13	
R10	Has_temporal Arg1:T18 Arg2:T19	
*	OR T20 T21
R11	Has_multiplier Arg1:T18 Arg2:T20	
R12	Subsumes Arg1:T12 Arg2:T15	
T1	Value 5 22	18 years or older
T2	Person 0 4	Aged
T3	Person 24 28	male
T4	Person 32 38	female
T5	Condition 41 63	Systolic heart failure
T6	Measurement 69 102	New York Heart Association (NYHA)
T7	Value 103 115	class II-III
T8	Measurement 118 159	Left ventricular ejection fraction (LVEF)
T9	Value 160 173	less than 40%
T10	Procedure 177 193	echocardiography
T11	Temporal 194 228	during screening and randomization
T12	Condition 231 234	SCH
T13	Measurement 236 239	TSH
T14	Value 241 278	upper limits of normal (ULN) -10mIU/L
T15	Measurement 284 293	FT4 level
T16	Value 294 316	within reference range
T18	Procedure 336 355	standard HF therapy
T19	Temporal 356 376	for at least 2 weeks
T20	Multiplier 393 404	target dose
T21	Multiplier 408 426	max tolerable dose
T23	Non-query-able 429 455	Provided informed consent.
